Jan 08, 2024 / 04:15PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Hey, good morning, everyone. We're going to get started. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, continuing the 42nd Annual Healthcare Conference this morning with Vertex. I'm joined by the company's CEO, Reshma Kewalramani. After the session, you don't have to switch rooms. We're going to go straight into Q&A. You're welcome to ask questions in the room. You can submit them to me on this iPad through the portal or you can listen to me ask questions. So with that, let me turn it over to Reshma for the presentation.
Reshma Kewalramani - Vertex Pharmaceuticals Incorporated - CEO, President & Director
Thanks, Jess. Jess, thank you very much. Thank you to JPMorgan. Good morning all. It's great to be here in San Francisco in person to kick off the year. On behalf of the entire Vertex team, I'm delighted to be here with you to give you an update on the CF business, our diversification into new disease areas with the near-term approval of casgevy and many more near
Vertex Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers